Product
Help
Pricing
About
Jobs
Log in
Get started
Funder
Add to collection
Peter MacCallum Foundation
Alternate names:
Peter MacCallum Cancer Foundation,
Peter Mac,
The Peter MacCallum Cancer Foundation
Country:
AU
ROR:
0395ye519
Crossref ID:
501100022084
DOI:
10.13039/501100022084
OpenAlex ID:
F4320331564
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
2018
·
Michael S Hofman
, John Violet
, et al.
·
The Lancet Oncology
·
1,229
The Lancet Commission on prostate cancer: planning for the surge in cases
2024
·
Nicholas D James
, Ian Tannock
, et al.
·
The Lancet
·
868
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
2019
·
Jeremie Calais
, Francesco Ceci
, et al.
·
The Lancet Oncology
·
493
PDF
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
2013
·
James D Mellor
, Michael P Brown
, et al.
·
Journal of Hematology & Oncology
·
423
PDF
Tumor immune evasion arises through loss of TNF sensitivity
2018
·
Conor J. Kearney
, Stephin J. Vervoort
, et al.
·
Science Immunology
·
389
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
2022
·
James P Buteau
, Andrew J Martin
, et al.
·
The Lancet Oncology
·
320
PDF
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
2018
·
Olga Kondrashova
, Monique Topp
, et al.
·
Nature Communications
·
316
PDF
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
2020
·
Benjamin J. Solomon
, Lavinia Tan
, et al.
·
Journal of Thoracic Oncology
·
313
PDF
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
2023
·
Michael S Hofman
, Louise Emmett
, et al.
·
The Lancet Oncology
·
247
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility
2020
·
Maria Teresa Landi
, D. Timothy Bishop
, et al.
·
Nature Genetics
·
241
PDF
The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer
2021
·
Stephin J. Vervoort
, Sarah A. Welsh
, et al.
·
Cell
·
216
PDF
First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
2019
·
Amit Khot
, Natalie Brajanovski
, et al.
·
Cancer Discovery
·
207
The molecular origin and taxonomy of mucinous ovarian carcinoma
2019
·
Dane Cheasley
, Matthew J. Wakefield
, et al.
·
Nature Communications
·
196
PDF
A Systematic Review on 3D-Printed Imaging and Dosimetry Phantoms in Radiation Therapy
2019
·
Rance Tino
, Adam Yeo
, et al.
·
Technology in Cancer Research & Treatment
·
182
PDF
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
2024
·
Silke Gillessen
, Fabio Turco
, et al.
·
European Urology
·
171
TheraP: a randomized phase 2 trial of 177 Lu‐ PSMA ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
2019
·
Michael S. Hofman
, Louise Emmett
, et al.
·
British Journal of Urology
·
166
PDF
Survivorship issues following treatment completion—results from focus groups with Australian cancer survivors and health professionals
2008
·
Michael Jefford
, Emily Karahalios
, et al.
·
Journal of Cancer Survivorship
·
162
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
2024
·
Arun A Azad
, Mathias Bressel
, et al.
·
The Lancet Oncology
·
152
PDF
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
2015
·
Rachel Ramsdale
, Robert N. Jorissen
, et al.
·
Science Signaling
·
143
Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth
2018
·
Helen B. Pearson
, Jason Li
, et al.
·
Cancer Discovery
·
138
PDF
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
2022
·
Silke Gillessen
, Andrew Armstrong
, et al.
·
European Urology
·
136
The Immune Microenvironment of Breast Cancer Progression
2019
·
Helen Tower
, Meagan Ruppert
, et al.
·
Cancers
·
121
PDF
Shared heritability and functional enrichment across six solid cancers
2019
·
Xia Jiang
, Hilary K. Finucane
, et al.
·
Nature Communications
·
113
Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial
2020
·
Rafael E. de Feria Cardet
, Michael S. Hofman
, et al.
·
European Urology
·
110
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma
2021
·
Ksenija Nesic
, Olga Kondrashova
, et al.
·
Cancer Research
·
100
PDF
Show more works
View as search
Works count:
331
Citation count:
13,200
H-index:
57
I10-index:
188
2-year mean citedness:
17.66
Awards count:
10
Year
Topic
Type
